PF-Atlas › Clinical Trials › NCT03725852

A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis

GLPG1205 · Phase 2

Registry ID

NCT03725852

Phase

Phase 2

Status

Completed

Drug / intervention

GLPG1205

Sponsor

Lakefront Biotherapeutics NV

Start

2018-09-27

Enrollment

Locations

About this trial

This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, exploratory Phase 2 study including participants with Idiopathic Pulmonary Fibrosis (IPF), investigating GLPG1205 in addition to the local standard of care (defined as receiving nintedanib, pirfenidone, or neither nintedanib nor pirfenidone).

View NCT03725852 on ClinicalTrials.gov →

Explore related

All GLPG1205 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03725852 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.